Shopping Cart

Your shopping cart is currently empty

Piroxicam

Name: Piroxicam
Brand: TargetMol
SKU: T0758
Price: 29 USD
Availability: InStock
Rating: 5 (10 reviews)

😃Good

Catalog No. T0758Cas No. 36322-90-4

Alias CP-16171

Piroxicam (CP-16171) is a non-specific COX inhibitor.

Piroxicam

😃Good

Purity: 99.52%

Catalog No. T0758Alias CP-16171Cas No. 36322-90-4

Piroxicam (CP-16171) is a non-specific COX inhibitor.

Pack Size	Price	USA Warehouse	Global Warehouse
1 g	$30	In Stock	In Stock
5 g	$113	-	In Stock
1 mL x 10 mM (in DMSO)	$29	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.52%

Appearance:Solid

Color:Yellow

Resource Download

COA HNMR LCMS

Product Introduction

Bioactivity

Description	Piroxicam (CP-16171) is a non-specific COX inhibitor.
Targets&IC50	COX-2 (human monocyte):25 μM, COX-1:47 μM
In vitro	Piroxicam induces activation of extracellular signal-regulated kinase (ERK) in neurones and phosphorylation of heavy molecular weight neurofilaments, cytoskeletal substrates of ERK in rat spinal cord cultures. Piroxicam and NS-398 protect neurones against hypoxia/reperfusion in rat spinal cord cultures. [1]
In vivo	Piroxicam at doses higher than 0.04%, strongly inhibits the development of GST-P-positive and neoplastic nodules as well as fibrosis, cirrhosis and formation of 8-hydroxydeoxyguanosine (8-OHdG) adducts in rats. [2] Piroxicam increases the expression of all three MHC antigens compared to either control or azoxymethane (AOM)-treated rats. Piroxicam up-regulates colonic MHC antigen expression in the AOM model of colonic carcinogenesis. [3] Piroxicam combined with Cisplatin has antitumor activity against oral malignant melanoma (OMM) and oral squamous cell carcinoma (SCC) in rats. [4] Piroxicam inhibits prostaglandin synthesis through cyclooxygenase blockade in dog, and Piroxicam does not have any direct cytotoxic effects in vitro. [5] Piroxicam also binds strongly to plasma proteins and Piroxicam could stop Ochratoxin A (OTA) -binding and transport into target organs, thereby preventing its nephrotoxicity in rats. Piroxicam prevents the enzymuria induced by OTA and increases renal elimination of OTA in rats. [6]
Synonyms	CP-16171

Chemical Properties

Molecular Weight	331.35
Formula	C₁₅H₁₃N₃O₄S
Cas No.	36322-90-4
Smiles	OC=1C=2C(S(=O)(=O)N(C)C1C(NC3=CC=CC=N3)=O)=CC=CC2
Relative Density.	1.563 g/cm3

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

Ethanol: 1 mg/mL (3.02 mM), Sonication is recommended.

DMSO: 45 mg/mL (135.81 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.04 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

Ethanol/DMSO

	1mg	5mg	10mg	50mg
1 mM	3.0180 mL	15.0898 mL	30.1796 mL	150.8978 mL

DMSO

	1mg	5mg	10mg	50mg
5 mM	0.6036 mL	3.0180 mL	6.0359 mL	30.1796 mL
10 mM	0.3018 mL	1.5090 mL	3.0180 mL	15.0898 mL
20 mM	0.1509 mL	0.7545 mL	1.5090 mL	7.5449 mL
50 mM	0.0604 mL	0.3018 mL	0.6036 mL	3.0180 mL
100 mM	0.0302 mL	0.1509 mL	0.3018 mL	1.5090 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc